LA JOLLA, Calif., Jan. 10 /PRNewswire/ -- Ambrx, Inc. today announced that Martin A. Mattingly, the Company’s president and chief executive officer, will present an overview of Ambrx’s research and development activities at the 24th Annual JPMorgan Healthcare Conference on Wednesday, January 11, at 9:00 a.m. Pacific time at the Westin St. Francis Hotel in San Francisco.
About Ambrx
Ambrx is transforming the science and performance of protein-based medicines. Ambrx’s unique technology is based upon a fundamental advance in protein biosynthesis that enables the selective incorporation of non-native amino acids into therapeutic proteins with the objective of optimizing their pharmaceutical properties. This approach represents a new paradigm in protein engineering and permits the optimization of proteins in a manner analogous to that used to improve the properties of small molecule-based drugs and peptides. Ambrx’s most advanced product candidate, ARX-201, is a patent-protected, long-acting human growth hormone. In preclinical studies, ARX-201 has demonstrated exceptional homogeneity, pharmacology and biophysical stability. The company expects to file an IND for ARX-201 in 2006 and owns all rights to the program. In addition, Ambrx is optimizing several other protein therapeutics representing large markets and significant unmet medical need.
Ambrx, Inc.
CONTACT: Troy Wilson of Ambrx, Inc., +1-858-875-2505
